Diarylsulfonylureas (DSU's) represent a new class of antitumor agent with a novel mechanism of action. Several analogues demonstrate high therapeutic efficacy in both rodent and human solid tumor systems. One compound, N-(5- indanylsulfonyl)-N'-(4-chlorophenyl)-urea (ISCU), currently in Phase I evaluation, is the most active agent that we have evaluated against advanced stage xenografts of human colon adenocarcinoma. Using human colon tumor models in vitro and in vivo it is proposed to elucidate the mechanism of cytotoxicity and examine the biochemical basis for therapeutic selectively for this class of agent. Preliminary data implicate mitochondria as a probable site of action. Our hypothesis is that energy dependent concentrative accumulation of DSU's in these organelles is a consequence of the pH differential across the matrix membrane, and that high concentrations of drug in mitochondria disrupt some function which leads to cell death. Using analogues with different potencies, mutant clones resistant to ISCU, ionophores and uncoupling agents, the relationship between mitochondrial accumulation of DSU's, pH dependence and cytotoxicity will be examined and the basis for sequestration established. Specific binding in mitochondria will be determined using a photoaffinity analogue. Subsequent studies will define functional changes in mitochondria both in intact cell and after isolation, that lead to cell death. The influence of proliferative status and hypoxia on cytotoxicity, and the potential to repair damage will be examined. The basis for therapeutic selectivity will be approached initially by study of the cellular pharmacology of DSU's in isolated cells from normal tissues of the mouse. Subsequently, distribution, accumulation and metabolism of analogues in xenografts of human colon adenocarcinomas sensitive or resistant to DSU's and in normal tissues of mice will be examined. These studies will facilitate defining mechanisms of action of DSU's and may identify new therapeutic targets which can be further exploited in treatment of human colon adenocarcinomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA051949-05
Application #
2094471
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1990-04-01
Project End
1996-02-28
Budget Start
1994-03-01
Budget End
1996-02-28
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Houghton, P J; Houghton, J A (1996) Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Invest New Drugs 14:271-80
Shu, L L; Houghton, P J (1996) Separation of resistance to antitumor diarylsulfonylurea agents from collateral sensitivity to mitochondrial toxins. Mol Pharmacol 49:595-601
Houghton, P J; Sosinski, J; Thakar, J H et al. (1995) Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol 49:661-8
Wadkins, R M; Houghton, P J (1995) Kinetics of transport of dialkyloxacarbocyanines in multidrug-resistant cell lines overexpressing P-glycoprotein: interrelationship of dye alkyl chain length, cellular flux, and drug resistance. Biochemistry 34:3858-72
Houghton, P J; Cheshire, P J; Myers, L et al. (1995) Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts. Anticancer Drugs 6:317-23
Sosinski, J; Thakar, J H; Germain, G S et al. (1994) Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea. Mol Pharmacol 45:962-70
Sosinski, J; Thakar, J H; Germain, G S et al. (1993) Proliferation-dependent and -independent cytotoxicity by antitumor diarylsulfonylureas. Indication of multiple mechanisms of drug action. Biochem Pharmacol 45:2135-42
Thakar, J H; Chapin, C; Berg, R H et al. (1991) Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions. Cancer Res 51:6286-91
Sosinski, J; Chapin, C; Thakar, J H et al. (1991) Influence of extracellular pH on the accumulation and cytotoxicity of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human cell lines. Cancer Commun 3:373-81